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RESUM
Les alteracions vasculars i degeneratives del sistema nerviós central (SNC) són dues de les
causes més comunes de malaltia i de mort entre la gent gran; ambdues es correlacionen amb
l’edat, amb la deficiència en GH, i poden afectar les funcions fisiològiques de la població d’edat
avançada.
Amb la finalitat de clarificar els efectes de la GH en el metabolisme, en els vasos i en el SNC,
hem dut a terme un estudi in vivo utilitzant rates velles Wistar tractades crònicament amb GH.
Les rates velles varen presentar un augment en el pes de greix i una disminució de l’índex
específic de gravetat (SGI) (p < 0,05) en comparar-les amb les rates adultes no tractades. La
GH va reduir el pes en greix (p < 0,05), i va mostrar també una tendència a augmentar l’SGI.
Es va analitzar també la resposta de diverses substàncies vasoactives en els anells aòrtics, i es
va demostrar una disminució de la vasodilatació per acetilcolina i isoprenalina (p < 0,05) en
els animals vells. La contracció induïda per acetilcolina+L-NAME era més alta en els animals
vells que en els adults. L’administració de GH millorava les respostes vasodilatadores (p < 0,05)
mentre que tendia a reduïr les respostes vasoconstrictores. L’àrea aòrtica mitja augmentava
també en les rates velles, mentre que la GH reduïa aquest paràmetre (p < 0,05).
Les poblacions neuronals es reduïen en els hipocamps de les rates velles en comparar-les
amb les joves. Aquesta reducció estava asociada a un augment dels nucleosomes i a una reduc-
ció de Bcl2 en el cervell. Les caspases 3 i 9 també varen augmentar. El tractament amb GH va
augmentar significativament el nombre de neurones i va reduir els nucleosomes i les caspases
i augmentar el Bcl2. En conclusió, el tractament per GH indueix l’aparició d’efectes beneficiosos
en la composició del cos i ha restablert també les funcions cerebrals i vasculars en les rates velles.Paraules clau: envelliment, GH, SNC, fisiologia vascular, neurones, metabolisme.
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SUMMARY
Vascular and degenerative alterations of the central nervous system (CNS) are two of the
most common reasons for illness and death in elderly people; they exhibit an age-related GH
deficiency that can affect their physiological functions.
A study was conducted under chronic in vivo conditions using old Wistar rats, in order to
clarify the effects of GH on the metabolism, vessels, and the CNS. The old rats showed an in-
creased fat weight and a decreased Specific Gravity Index (SGI) (p < 0.05), as compared to the
adult animals. GH reduced the fat weight (p < 0.05) and tended to increase the SGI (N.S.). The
response to several vasoactive substances in aortic rings showed impaired vasodilatation to
Acetylcholine and Isoprenaline (p < 0.05) in the old animals. Contraction, induced by Acetyl-
choline+L-NAME, was higher in the old rats than in the adults. GH administration improved
the vasodilatory responses (p < 0.05) and tended to reduce the constrictory responses. The aortic
media area was increased in the old rats, and GH reduced this parameter (p < 0.05).
The neuronal populations were reduced in the hippocampi of the old rats as compared to the
young ones. This reduction was associated with an increase in nucleosomes and a reduction
in Bcl2 in the brain. An increase was also detected in caspases 3 and 9. GH treatment was able
to significantly enhance the number of neurons by reducing the nucleosomes and the caspases
and by increasing Bcl2. In conclusion, GH treatment was able to show beneficial effects on body
composition and was able to restore both vascular and brain functions in the old rats.Keywords: Aging, GH, CNS, vascular physiology, neurons, metabolism.
INTRODUCTION
Growth hormone (GH) is the most abun-
dant anterior pituitary hormone; it accounts
for 4-10 % of the wet weight of the anterior
pituitary in the human adult, amounting to
about 5-10 mg per gland (Arce and Devesa,
2000).
GH of mammalian origin is active in many
species, but humans are responsive only to
human or primate GH (Hadley, 1992). GH is
similar in structure to prolactin and placental
lactogen.
The circulating levels of this hormone de-
cline during the first weeks after birth, but
they reach adult levels after two or three
weeks of life. A substantial increase in GH has
been observed during puberty. Spontaneous
episodes of GH secretion occur every 3-4
hours over a 24-hour period, with these secre-
tory peaks being more frequent and smaller
in females than in males (Tannenbaum, 1988).
The highest secretion of GH occurs during the
two first hours of nocturnal rest during the pe-
riod of slow wave sleep.
Three hypothalamic hormones are involved
in GH control: somatostatin (SS), GH Releas-
ing Hormone (GHRH) and ghrelin, which is
also synthesized in the stomach (Kojima et al.,
1999).
SS has an inhibitory effect on GH release in
response to every known stimulus. The action
of SS is exerted directly upon pituitary soma-
totrophs (Tannenbaum, 1988).
SS also inhibits TRH-induced TSH secre-
tion, renin, parathormone, calcitonin, gastric
HCl, acetylcholine and other neurotransmit-
ters, blood platelet aggregation, brain cell
electrical activity, and many other physiolog-
ical processes.
GHRH was isolated in 1982 from two pan-
creatic tumors and was found to specifically
stimulate GH secretion both in vivo and in
vitro (Guillemin et al., 1982; Rivier et al.,
1982). Hypothalamic GHRH has been found
to be bound to specific receptors in the soma-
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totrophic cells and to stimulate GH secretion,
cell proliferation, and also the GH-gene tran-
scription (Vance, 1990).
Each episodic secretion of GH is deter-
mined by the release of GHRH to the portal
circulation, together with a decrease in so-
matostatin. This pulsatile pattern in the secre-
tion of GH seems to be more important to the
peripheral hormonal effects than to the total
amount of secreted GH (Devesa et al., 1992).
Ghrelin is a recently discovered peptide
with 28 amino acids, synthesized mainly in
the stomach mucosa, though it is also pro-
duced in the hypothalamus. This peptide is
able to stimulate GH release both in vivo and
in vitro. (Date et al., 2000).
Other neurotransmitters, such as NA, DA,
Ach, Serotonin, and/or GABA also play a role
in GH secretion. The secretion of GH is also
influenced by the endocrine system (García
Barros and Devesa, 2000).
ACTIONS OF GH
GH acts on the tissue of a receptor (GHR)
that consists of a transmembranous protein of
620 amino acids, codified by a gene located
on chromosome 5 (García Barros and Devesa,
2000).
GH is an anabolic protein hormone that
produces a positive nitrogen and phosphorus
balance (Davidson, 1987). GH causes cells to
grow and multiply by directly increasing the
rate at which amino acids are used to synthe-
size proteins. Due to these effects, GH induces
an increase in the growth rate of long bones
and skeletal muscles during childhood and
the teenage years.
GH stimulates lipolysis, which is the break-
down of triglycerides into fatty acids and
glycerol. It provides substrates for glucose
neosynthesis and, thus, has a sparing effect on
glucose utilization. GH also promotes fat ca-
tabolism (García Barros and Devesa, 2000).
In normal subjects, GH stimulates insulin
secretion, but at the same time, this hormone
reduces the sensitivity of peripheral tissues,
such as muscle and/or adipose tissue, to in-
sulin. Elevated plasma glucose levels then
stimulate insulin secretion and lead to a dia-
betogenic effect.
The absence of GH secretion in young chil-
dren leads to dwarfism, whereas its overpro-
duction during the postnatal period produces
gigantism. In the adult, an excess of GH leads
to acromegaly (Isaksson et al., 1988).
A GH deficiency in an adult has been re-
cently recognized as a specific clinical syn-
drome, characterized by a combination of
metabolic and cardiovascular features that are
more evident in women than in men (Hew,
1998). This syndrome includes a high preva-
lence of dyslipidaemia, glucose intolerance,
central obesity, and hypertension. Early ar-
teriosclerosis is found in this asymptomatic
hypopituitary GH deficiency. All of these are
important contributory factors to an increased




The secretion of GH and IGF decrease with
increased age; elderly people exhibit very low
levels of GH and IGF I, as compared to young
people (Todgood and Shalet, 1998). Metabolic
changes also occur with aging, such as the
diminution of muscular and osseous masses
or the increment of adipose tissue. A rela-
tionship between these two circumstances has
been detected and the term “somatopause”
has been proposed to describe this situation
(Hoffman et al., 1993).
Aging is associated with several changes
and alterations in the metabolism, body com-
position and organ functions (Ariznavarreta
et al., 2003). Elderly people show bone mineral
density loss, lean body mass and muscular
strength reduction, adipose tissue increase, in-






















*** p < 0.001 vs M24m 
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Figure 1. Effect of the treatment with GH on the number of
neurons on the de hilus of the dentate gyrus of the hippocampus
in 24 months old rats as compared with 22 and 24 months old
untreated rats.
sulin resistance and glucose intolerance, etc.
(Savine and Sönksen, 1999; Toogood et al.,
1996; Toogood and Shalet, 1998). Similarities
have been detected in all of the consequences
of GH deficiency (GHD) in adults and the
changes observed in elderly people. These
similarities point to a possible relationship be-
tween age-related physical impairment and
the GH/IGF-1 axis decline that physiologi-
cally occurs with age (Toogood et al., 1996;
Toogood and Shalet, 1998; Ghigo et al., 2001).
Old age could be a physiological state of GH-
deficiency.
Indeed, experimental evidence has demon-
strated that GH treatment has beneficial ef-
fects on aged animals. It improves cerebral
microvasculature (Sontag et al., 1997), coro-
nary blood flow, and heart capillary density
in aging rats (Khan et al., 2001).
In humans, GH treatment is able to enhance
lean body mass and muscular strength, re-
duce body fat (Cuttica et al., 1997; Holloway
et al., 1994; Rudman et al., 1990), improve the
plasma lipid profile (25), and increase bone
mineral density (Rudman et al., 1990). How-
ever, the effects of GH on vascular functions
and structure in aged individuals are not well
established.
In addition to their effects on somatic
growth and metabolism, the hormones of the
somatotrophic axis (i.e., Growth Hormone-
Releasing Hormone (GHRH), Growth Hor-
mone (GH) and Insulin-like Growth Factor-
1 (IGF-1)) also exert some other actions on
the cardiovascular system (Arce and Devesa,
2000).
EXPERIMENTAL DESIGNS
Male and female Wistar rats (22 months
of age) were used in the study, and a group of
young animals (3 months of age) was consid-
ered the control group. Ten animals per group
were used.
Old rats were treated with saline solution or
with GH twice a day at a dose of 1 mg/kg/day
or 2/kg/kg/day for one month. The Specific
Gravity Index (SGI), which represents the in-
dex: air weight / (air weight – water weight)
× 0.9979 (specific gravity of water), was mea-
sured. Plasma levels and tissue concentrations
of IGF-I in the liver and muscle were deter-
mined using a specific R.I.A. method after
extraction with acid ethanol (Rol de Lama et
al., 2000).
Aortic rings (3 mm) were connected to a
force transducer attached to a computer (Mc
Lab 8E, AD Instruments) to evaluate vascular
reactivity.
The CNS was immediately dissected to ob-
tain discrete areas. Parts of them were imme-
diately frozen at –80o C to be further submit-
ted for homogenization, in order to be ana-
lyzed for Bcl2 and nucleosomes or for RNA
extraction for Real Time PCR. The other areas
of CNS were fixed in 4% paraformaldehyde in
phosphate buffer, stained with Nissl staining
and submitted to histological and histochem-
ical studies, counting the number of neurons
in the hilus of the dentate gyrus.
METABOLIC EFFECTS
Adults with GH-deficiency exhibit a dimi-
nution of their lean body mass and an increase
in adipose tissue, which means a reduction
in the muscular force capacity (Rosen et al.,
1993; Toogood and Shalet, 1998; Callum et



















** p < 0.01 vs M24m 
Figure 2. Effect of the treatment with GH on the levels of
nucleosomes in cerebral homogenates of 24 months old rats as
compared with 24 months untreated old rats.
al., 2002). An increase in force and exercise
capacity has been reported in elderly people,
when GH therapy has been instituted (Cuttica
et al., 1997; Juul, 1996; Salomon et al., 1989). In
our study, the results indicated that GH treat-
ment in the old rats decreased fat tissue and
increased muscular mass, as reflected by the
increment in the SGI (see figure 1). The higher
this index was, the higher the muscular mass
and the smaller the quantity of fat. Treatment
with GH also increased plasmatic, hepatic and
muscular IGF-I in the old rats. An increase in
weight gain was also observed.
In our study, the old rats showed an in-
crease in epididimary and periuterine fat, to-
gether with a reduction in the SGI of the
male carcasses, which meant that adiposity
was augmented and the lean body mass was
reduced. GH administration reduced epididi-
mary and periuterine fat and increased SGI
in the old rats of both sexes, which meant
that this treatment was able to increase muscle
mass and reduce fat (Castillo et al., 2003).
As regards body composition, our data
were consistent with previous studies ob-
tained in our laboratory (Pérez Romero et
al., 1999). SGI is an index that relates lean
body mass and fat mass; the higher it is, the
less fat the animal has. In our study, rats
showed an increase in epididimary and peri-
uterine fat, together with a reduction in the
SGI of the male and female carcasses, which
meant that adiposity was augmented and lean
body mass was reduced. GH administration
reduced epididimary and periuterine fat and
increased SGI in the old rats of both sexes,
which meant that this treatment was able to
increase muscle mass and reduce fat. It has
been demonstrated that GH treatment in both
GHD adults and elderly people is able to
improve several parameters related to body
composition (Rudman et al., 1990; Mc Callum
et al., 2002; Bengston et al., 1993). A good ex-
ample of this is reducing abdominal obesity,
which is a strong predictor of cardiovascu-
lar risk (Despres et al., 1998). The increment
in SGI in old GH-treated rats is associated
with an increase in body weight gain, as com-
pared to the weight loss observed in old un-
treated animals. This confirms the preponder-
ance of the anabolic properties of GH in the
old animals over the lypolitic effects on fat tis-
sue.
It has been previously reported that there
is a decrease in GH and IGF-1 production
with age (Castillo et al., 2003). However, in the
present study, reduced plasma IGF-1 levels
were only seen in males, whereas hepatic IGF
1 content was significantly reduced in both
sexes (Castillo et al., 2005). GH administration
was able to significantly increase the hepatic
content and plasma IGF-1 levels.
VASCULAR EFFECTS
Aging is associated with both structural and
functional changes that take place in the vas-
cular wall (Matz et al., 2000; Maeso et al., 1999).
Aging reduces endothelium-dependent relax-
ation, in response to different agonists, and
it increases endothelium-dependent contrac-
tion. There is also an increase in the media-
intima thickness, as well as changes in the
cellular and extra-cellular composition of the
vessel wall (Maeso et al., 1999).
GH-deficient patients show a greater risk
of cardiovascular alterations (Rosen, 1990)
and endothelial dysfunctions, including a re-




















*** p < 0.001 vs M24m 
Figure 3. Effect of the treatment with GH on the levels of Bcl-
2 on cerebral homogenate of 24 months old rats as compared with
24 months old untreated rats.
duced vascular endothelial-dependent relax-
ation (Evans et al., 1999).
Aging is associated with an impaired en-
dothelium-dependent vasodilatation. This is
suggested by the reduced response to both
acetylcholine and isoprenaline in old rats, as
compared to young ones, without changes in
the endothelium-independent relaxation, as
shown by the absence of differences in the re-
sponse to sodium nitroprusside (Maeso et al.,
1999; Koga et al., 1998; Tominaga et al., 1994).
Similar results have been obtained in exper-
iments carried out on humans, measured as
responses to the brachial arterial infusion of
acetilcholine by pletismography (Andrawis et
al., 2000). This endothelial dysfunction seems
to parallel the general deterioration of the an-
imals, as shown by the correlation found be-
tween the maximal relaxation to acetylcholine
and the body composition parameters.
A decrease in endothelial NO availability,
due to reduced synthesis and/or major degra-
dation by oxidative stress, has been suggested
as an important mechanism, underlying the
altered response to endothelium-dependent
agents during aging (Matz et al., 2000; Maeso
et al., 1999; Tachudi. et al., 1996; Loo et al.,
2000). In addition, an increase in contracting
factors, which can counteract the effects of
relaxing ones, could also be involved in this al-
tered endothelial function. This notion is sup-
ported by the fact that senescent animals show
a higher response to acetylcholine+LNAME
than young ones, as shown in the present
study. A similar increase in endothelium-de-
pendent contraction has been previously re-
ported (Koga et al., 1998; Küng and Lüscher,
1995). Thromboxane A2 or PGH2 have been
proposed as the agents accounting for the
increase in endothelium-dependent contrac-
tion with aging (Matz et al., 2000). Moreover,
the changes observed in the structure of the
vascular wall could be an additional mecha-
nism involved in the impairment of endothe-
lial function, since there is a negative correla-
tion between the maximal relaxation to acetyl-
choline and the media cross-sectional area. In
fact, these changes could partially explain the
reduction in phenylephrine contraction ob-
served in the old rats, due to alterations in
the contractile machinery of the smooth mus-
cle cells. In our study, the administration of
GH to old rats produced an expected increase
in the plasma levels of IGF-1, which was ac-
companied by an improvement in endothelial
function and vessel structure (Castillo et al.,
2003, 2005).
The possible mechanisms, underlying the
beneficial effects exerted by GH administra-
tion, could involve an increase in endothelial
NO availability. This affirmation is based on
the fact that several studies have shown that
GH-induced IGF-1 is not only able to stimu-
late NO synthesis in endothelial cells (Boger,
1999; Boger et al., 1996), but it can also de-
crease NO degradation by reducing oxidative
stress production (Evans et al., 2000; Castillo
et al., 2004). This enhanced NO availability
could positively influence vascular function
and structure. Another possible mechanism
could involve the decrease in the vasocon-
strictor agents previously mentioned, such as
Thromboxane A2 or PGH2, which could coun-
teract NO actions; this has been shown by
the tendency towards a reduction of endothe-
lim-dependent contraction by GH. These data
confirm previous studies, which have shown
that GH can exert beneficial effects on the car-
diovascular system of aged animals (Sontag et
al., 1997; Khan et al., 2001).



























** p < 0,01 vs Hint 24m* p < 0,05 vs Hint 24m
Caspase-3 
Caspase-9 
Figure 4. Effect of the treatment with GH on the expresion of
Caspase-3 and Caspase-9 in the hypothalamus of 24 months old
rats as compare with 24 months old untreated rats.
EFFECTS ON CNS
The hippocampus, a brain region involved
in spatial and episodic memory (may signifi-
cantly contribute to the age-associated decline
in cognitive abilities. Although in most brain
areas there is no massive neuronal loss with
aging, a significant reduction in the number of
neurons has been reported in the hilus of the
dentate gyrus of the hippocampal formation
in aged humans and in 24 month-old Fischer
344 male rats.
It is well known that GH exerts important
effects on the CNS (Nyberg, 2000), increasing
the psychological capacity of adults, mem-
ory, concentration, alertness, and the capacity
for work (Burman et al., 1995). Some neuro-
transmitters also change under GH treatment
(Johanson et al., 1995; Segovia et al., 2001).
Receptors for GH exist in the CNS at differ-
ent levels: neurons, glia, and endothelial cells
in the vessels (Lobil et al., 1993). Under GH
stimulation IGF-I is produced in the cerebral
tissue (López Fernández et al., 1996), probably
playing a local trophic role (Torres Aleman, et
al,. 1994). The emergence of new neurons in
the brain is a well- documented phenomenon,
especially in young animals, though the real
significance of this fact is still unknown (Trejo
et al., 2001).
Using an unbiased stereological estimation
of the total number of neurons in the hilus of
the dentate gyrus of the rat hippocampus, we
detected the following: there was a significant
sex dimorphism in neuronal content, a preser-
vation of neuronal content until 22 months of
age, and a significant neuronal loss between
22 and 24 months of age in both sexes (Az-
coitia et al., 2005). Our present findings indi-
cated that the number of hilar neurons was
also sexually dimorphic in the rat, with males
exhibiting more neurons than females. The
sex difference was detected in young adult
rats and was maintained until 24 months of
age. The sex differences in hippocampal struc-
ture and function may be a consequence of the
perinatal effects of testosterone on male rats.
In addition, sex steroids affect the adult hip-
pocampus and may protect adult hilar neu-
rons from excitotoxic cell death. The neuronal
counts were not significantly different at 3
months of age compared to 22 months, an ad-
vanced age for rats. However, between 22 and
24 months of age there was a clear deteriora-
tion in the structure of the hilus. Our findings
were also in agreement with a previous report,
showing a significant neuronal loss in the hili
of 24 month-old male Fischer 344 rats, com-
pared to 12 month-old animals.
The stereological estimation of the total
number of hilar neurons revealed that 24
month-old rats that were treated with GH had
more neurons in the hilus than control ani-
mals, treated with vehicle (see figure 1). The
neuroprotective effect of GH was observed in
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both sexes. GH is a neuroprotective factor for
the brain and spinal cord of young animals,
and it prevents hippocampal neuronal cell
loss after unilateral hypoxic-ischaemic brain
injury. In young animals, the neuroprotective
effects of GH appear to be mediated, at least
in part, by the activation of GH receptors.
Furthermore, it is known that the administra-
tion of GH to old rats increases IGF-I expres-
sion in the brain, including the hippocampus.
Since IGF-I is a neuroprotective factor for hilar
neurons, the local production of this mole-
cule may mediate the neuroprotective effects
of GH. Our present findings indicated that
GH could protect hilar hippocampal neurons
from degeneration, associated with aging. The
measurements of nucleosomes in brain ho-
mogenate showed an age related increase that
was accompanied by a reduction in Bcl2, an
apoptosis protective protein. The increase in
nucleosomes was also associated with an in-
crease in caspases 3 and 9. After GH treat-
ment, a clear inhibition of apoptosis was ob-
served, which was accompanied by a decrease
in nucleosome levels (see figure 2) and an
increase in Bcl-2 levels (see figure 3). These
changes could have been due to the activa-
tion of intracellular signals, either directly by
GH or by IGF I activation, the levels of which
were increased after the systemic GH admin-
istration (Frago, 2002). A possible mechanism
is the inhibition that GH and/or IGF I exert
on Pl3-quinase, which mediates the phospho-
rylation of Akt/protein-quinase (Akt/PKB)
(Frago, 2002). The result is that Bad is phos-
phorylated (Datta et al., 1997), since it is un-
able to bind anti-apoptotic proteins, such as
Bcl-2, so that this protein increases. On the
other hand, Akt/PKB is able to activate the
transcription factor CREB, which also stimu-
lates Bcl-2 expression. Increased Bcl-2 could
be responsible, first, for decreased caspase-9
and subsequently, for a decrease in caspase-3
(see figure 4).
In conclusion, GH treatment for 10 weeks
in old male rats was able to restore vascular
functions and structure and prevent neuronal
apoptosis in the CNS.
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